Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095810 · ClinicalTrials.gov registry record · Phase 4
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
A Phase 4 study of Parkinson's Disease and Psychoses, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00095810: Completed Phase 4 study of Parkinson's Disease and Psychoses, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT00095810 is a Phase 4 study of Parkinson's Disease and Psychoses that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 50 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00095810, a Phase 4 study of Parkinson's Disease and Psychoses, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
Conditions Studied
Interventions
- DRUG aripiprazole
Study Locations (1)
New York
- Local Institution - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-07 |
| Est. Completion | 2004-09 |
| Phase | Phase 4 |
What the finished NCT00095810 record still lists
NCT00095810 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which aripiprazole is the first listed.
NCT00095810 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00095810 about?
NCT00095810 is a clinical study titled "Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease". The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
What is the current status of trial NCT00095810?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2003-07. Estimated completion is 2004-09.
What conditions does trial NCT00095810 study?
This clinical trial studies the following conditions: Parkinson's Disease, Psychoses.
What interventions are being tested in trial NCT00095810?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00095810?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00095810 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00095810's enrollment target sits among peer trials
50 82nd of 158 higher than 73 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Validation of Dyskinesia Rating Scales
COMPLETED · Phase 4
-
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
COMPLETED · Phase 4
-
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
COMPLETED · Phase 4
-
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
COMPLETED · Phase 4
-
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
COMPLETED · Phase 4
-
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia